# Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial

> **NCT01400516** · PHASE4 · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 26 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Teriparatide
- **DRUG:** calcium citrate
- **DRUG:** Vitamin D
- **DRUG:** TNF antagonist

## Key facts

- **NCT ID:** NCT01400516
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2015-07-30
- **Final completion:** 2016-07-28
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2017-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01400516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01400516, "Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01400516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*